

## New Publication

January 28, 2021

### KILLER ACQUISITIONS IN INDIAN PHARMA - EMERGING TRENDS

Emerging Trends

January 28, 2021



Known as the pharmacy of the world, India accounts for 20% of the volume of global drug production. However, innovation in this sector is yet to see its time in the sun, with the industry only gradually increasing its R&D expenses to develop new and innovative drugs as well as drug delivery mechanisms. It is during this phase that it becomes even more important to protect innovation, not only from an intellectual property point of view, but also from an antitrust perspective.

'Killer' acquisitions (a practice of well-established firms acquiring 'nascent' competitors), a trend that is already prevalent in foreign markets, have the potential to stifle the pharmaceutical industry's gradual move from a generic to an innovative sector. While India has not seen these kinds of acquisitions to a large extent, the question still remains – are Indian antitrust laws sufficient to protect the market and promote innovation, while maintaining healthy competition?

In this paper, the authors discuss the global trend of killer acquisitions, and analyze whether the Indian antitrust law is sufficiently equipped to deal with them, along with options that companies have, if faced with such a situation.

The paper can be accessed [here](#).

For any help or assistance please email us on [ndaconnect@nishithdesai.com](mailto:ndaconnect@nishithdesai.com).

Do visit us at [www.nishithdesai.com](http://www.nishithdesai.com).

**Benchmark Litigation Asia-Pacific:** Tier 1 for Government & Regulatory and Tax  
2020, 2019, 2018

**Legal500 Asia-Pacific:** Tier 1 for Tax, Investment Funds, Labour & Employment and TMT  
2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012

**Chambers and Partners Asia-Pacific:** Band 1 for Employment, Lifesciences, Tax and TMT  
2020, 2019, 2018, 2017, 2016, 2015

**IFLR1000:** Tier 1 for Private Equity and Project Development: Telecommunications Networks.  
2020, 2019, 2018, 2017, 2014

**AsiaLaw Asia-Pacific Guide 2020:** Ranked 'Outstanding' for TMT, Labour & Employment, Private Equity, Regulatory and Tax

**FT Innovative Lawyers Asia Pacific 2019 Awards:** NDA ranked 2nd in the Most Innovative Law Firm category (Asia-Pacific Headquartered)

**RSG-Financial Times:** India's Most Innovative Law Firm  
2019, 2017, 2016, 2015, 2014

#### Who's Who Legal 2020:

- Nishith Desai- Thought leader (Corporate Tax 2020, India 2020), Global leaders (Private Funds 2020)
- Vikram Shroff-Global Leaders (Labour & Employment 2020, Pensions & Benefits 2020)
- Milind Antani- Pharma & Healthcare – only Indian Lawyer to be recognized for 'Life sciences - Regulatory,' for 5 years consecutively

## Research Papers

### Mergers & Acquisitions

July 11, 2025

### New Age of Franchising

June 20, 2025

### Life Sciences 2025

June 11, 2025

## Research Articles

### 2025 Watchlist: Life Sciences Sector India

April 04, 2025

### Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

### INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

## Audio

### CCI's Deal Value Test

February 22, 2025

### Securities Market Regulator's Continued Quest Against "Unfiltered" Financial Advice

December 18, 2024

### Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

## NDA Connect

Connect with us at events, conferences and seminars.

## NDA Hotline

Click here to view Hotline archives.

## Video

### Reimagining CSR: From Grant Giving to Blended Finance & Outcome Based Funding

June 16, 2025

### Courts vs Bankruptcy code: The

The contents of this publication should not be construed as legal opinion. View detailed disclaimer.

This Publication provides general information existing at the time of preparation. The Publication is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Publication. It is recommended that professional advice be taken based on the specific facts and circumstances. This Publication does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.